Response to Neoadjuvant Chemotherapy in Breast Cancer Could be Predictable by Measuring a Novel Serum Apoptosis Product, Caspase-Cleaved Cytokeratin 18: A Prospective Pilot Study
about
Elevation of serum fortilin levels is specific for apoptosis and signifies cell death in vivo.Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patientsBiomarker method validation in anticancer drug developmentClinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer.Circulating Levels of M30 and M65 Molecules in Transitional Cell Carcinoma of the Bladder and Their Relation to Tumor Progression.Investigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancer.Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.Serum efficacy biomarkers for oncology.Apoptosis: why and how does it occur in biology?The M30 assay does not detect apoptosis in epithelial-derived cancer cells expressing low levels of cytokeratin 18.Methods to Evaluate Cell Growth, Viability, and Response to Treatment in a Tissue Engineered Breast Cancer Model.A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer.Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.Prognostic value and clinicopathological significance of serum- and tissue-based cytokeratin 18 express level in breast cancer: a meta-analysis.Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma.
P2860
Q34795048-1D709353-63CC-4226-9561-29507BD9A28DQ36177752-6B73F3E3-3038-46D4-8E73-A87D3F4D2A00Q36484621-4B951172-23B0-46A6-9B3F-7CBABCA7CBBAQ36897795-7EB059DC-8A61-417C-ABCE-864193EE3624Q36980678-2C62DCDD-0FF4-493C-B366-13732B0CE5DDQ37111059-86CB2368-182F-4606-BED9-DBC7D9C88D70Q37705010-A4C80937-CA42-4F79-905F-9E75AB2F2F3EQ37724878-5C1EF9BB-11F1-4A9B-8716-B06A2945CBA3Q37755150-95830245-9FC3-4412-A5E4-02ED8B2257F0Q37902996-0F37A8C2-8A4B-4842-9B9C-367BE475448BQ38890416-3F3CE48C-73ED-452D-9EEF-E23D6204BD8CQ42621191-2CC637D8-CEAD-4114-982E-B6F3ED143D7EQ43421009-FBC40909-087A-4014-AC84-6CAA05BB70D4Q46326788-3118970C-2F83-4D1F-9A89-E9A9566E0DEFQ50043508-AEC0EBC8-5A91-454A-A4A1-03A8F98D586AQ50893230-477BEA40-631D-4D1D-82A1-8ED170F5D9E7
P2860
Response to Neoadjuvant Chemotherapy in Breast Cancer Could be Predictable by Measuring a Novel Serum Apoptosis Product, Caspase-Cleaved Cytokeratin 18: A Prospective Pilot Study
description
article
@en
im Januar 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2006
@uk
name
Response to Neoadjuvant Chemot ...... 18: A Prospective Pilot Study
@en
Response to Neoadjuvant Chemot ...... 18: A Prospective Pilot Study
@nl
type
label
Response to Neoadjuvant Chemot ...... 18: A Prospective Pilot Study
@en
Response to Neoadjuvant Chemot ...... 18: A Prospective Pilot Study
@nl
prefLabel
Response to Neoadjuvant Chemot ...... 18: A Prospective Pilot Study
@en
Response to Neoadjuvant Chemot ...... 18: A Prospective Pilot Study
@nl
P2093
P2860
P1433
P1476
Response to neoadjuvant chemot ...... 18: a prospective pilot study
@en
P2093
Engin Engin Ulukaya
Murat Arslan
Mutlu Demiray
Osman Manavoglu
Ozlem Saraydaroglu
Sehsuvar Gokgoz
Turkkan Evrensel
P2860
P304
P356
10.1080/07357900600981307
P50
P577
2006-11-01T00:00:00Z